LAWRENCEVILLE, N.J. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or approximately one-third of the total, have been enrolled at 22 sites, including 20 patients in the treatment

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical stage development company focused on DNA based immunotherapy and next generation vaccines,

Celsion’s Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases  Granted an Accelerated Development Pathway Designation Provides Potential for an Expedited Regulatory Review. LAWRENCEVILLE, N.J. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a

Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced the formation

Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study, and Phase III OPTIMA Study Conclusions LAWRENCEVILLE, N.J. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced that Michael H.

The PLACCINE Platform Technology is Conceived to Enable Rapid Development of Vaccines That Can Address a Broad Range of Infectious Agents, including SARS-Associated Coronavirus (SARS-CoV) Patent Filing Claims a Novel Composition of Multiple Antigens and Use of a Synthetic Nano Delivery Technology

Lawrenceville, NJ , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced

LAWRENCEVILLE, NJ , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of

         Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: